冠狀病毒是一類廣泛存在、可感染人畜并引起嚴重急慢性呼吸道系統(tǒng)疾病的病原體。3-胰凝乳蛋白酶樣蛋白酶（3CL蛋白酶）是一種位于冠狀病毒非結構蛋白nsp5上的半胱氨酸蛋白酶，被認為是廣譜抗冠狀病毒極具吸引力的靶標之一。擬肽類3CL蛋白酶抑制劑具有更高的靶向性、更廣泛的抑制譜、更低的不良反應?？偨Y了已上市的奈瑪特韋、來瑞特韋、先諾特韋、阿泰特韋和處于臨床試驗階段的擬肽類3CL蛋白酶抑制劑的研究進展。

Coronavirus is a type of pathogen that is widely present, can infect humans and animals, and cause serious acute and chronic respiratory system diseases. 3-Chymotrypsin like protease (3CL protease) is a cysteine protease located on the non-structural protein nsp5 of the coronavirus, and is considered one of the highly attractive targets for broad-spectrum anti coronavirus therapy. Peptide 3CL protease inhibitors have higher targeting, wider inhibition spectrum, and lower adverse reactions. This article summarizes the research progress of the marketed drugs such as nirmatrelvir, leritrelvir, simnotrelvir, atilotrelvir, and the peptide 3CL protease inhibitors currently in clinical trials.

R974

國家自然科學基金青年科學基金項目（82204207）